A Phase 3 interventional study of Fluticasone Propionate and Fluticasone Propionate/Salmeterol in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 118 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 12th largest by enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2016, is one of 35 in phase 3, and was the 126th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 841 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 9th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2016, is one of 30 in phase 3, and was the 44th registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety and efficacy of fluticasone propionate and fluticasone propionate salmeterol in pediatric participants with a documented history of persistent asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must be able to replace their current SABA with albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) inhalation aerosol at the SV for use as needed for the duration of the study.
Exclusion Criteria:
Vulnerable participants (that is, people kept in detention) are excluded from participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
Drug: Placebo MDPI
Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
Drug: Fluticasone Propionate
Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
Drug: Fluticasone Propionate
Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
Drug: Fluticasone Propionate/Salmeterol
Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
Drug pages: Fluticasone · Salmeterol Xinafoate
Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
Matching placebo was administered via MDPI per the schedule specified in the arm.
For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \[Day 1\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (±10 minutes) postdose lung function assessments on Week 12 at the investigational center.
Time frame: Baseline, Week 12
For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.
Time frame: Baseline, Week 12
Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.
Time frame: Baseline, Week 1 to 12
Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12
Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \[Day 1\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).
Time frame: Baseline, Week 1 to 12
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12
Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.
Time frame: Baseline, Week 1 to 12
Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period
C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score ≤5) to complete control of asthma (score ≥25), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.
Time frame: Baseline, Week 1 to 12
Time to First Onset of Effect
The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \[HFA MDI\] \[90 mcg ex actuator\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.
Time frame: Baseline up to Week 12
Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period
Time frame: Baseline up to Week 12
| Milestone | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Started | 209 | 211 | 210 | 211 |
| Received at least 1 dose of study drug | 209 | 211 | 208 | 211 |
| Completed | 202 | 206 | 203 | 205 |
| Not completed | 7 | 5 | 7 | 6 |
| Withdrew: Other than specified | 1 | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 6 | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \[Day 1\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (±10 minutes) postdose lung function assessments on Week 12 at the investigational center.
| percent predicted of FEV1 | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|
| For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12 | 16.8 ± 1.32 | 16.4 ± 1.32 | 18.2 ± 1.29 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.
| percent predicted of FEV1 | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID |
|---|---|---|---|
| For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12 | 7.3 ± 1.10 | 13.3 ± 1.09 | 14.2 ± 1.10 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \[Day 1\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \[Day 1\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.
| liters/minute | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period | 12.3 ± 2.65 | 28.9 ± 2.62 | 26.3 ± 2.64 | 32.0 ± 2.61 |
Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \[Day 1\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).
| inhalations | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12 | -0.2 ± 0.05 | -0.4 ± 0.05 | -0.5 ± 0.05 | -0.4 ± 0.05 |
Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.
| units on a scale | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12 | -0.1 ± 0.02 | -0.2 ± 0.02 | -0.2 ± 0.02 | -0.2 ± 0.02 |
C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score ≤5) to complete control of asthma (score ≥25), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.
| units on a scale | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period | 4.5 ± 0.21 | 5.1 ± 0.21 | 5.5 ± 0.21 | 5.4 ± 0.21 |
The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \[HFA MDI\] \[90 mcg ex actuator\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.
| days | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Time to First Onset of Effect | 20.0 (5.0 to NA) | NA (3.0 to NA) | 2.0 (2.0 to 2.0) | 6.0 (2.0 to NA) |
| percentage of participants | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period | 6 | 2 | 1 | 2 |
Collected over Baseline up to Week 13. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo MDPI | 0/209 (0%) | 1/209 (0.5%) | 11/209 (5.3%) |
| Fp MDPI 25 mcg BID | 0/211 (0%) | 2/211 (0.9%) | 8/211 (3.8%) |
| Fp MDPI 50 mcg BID | 0/208 (0%) | 1/208 (0.5%) | 11/208 (5.3%) |
| FS MDPI 50/12.5 mcg BID | 0/211 (0%) | 4/211 (1.9%) | 9/211 (4.3%) |
| Event | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| Disruptive mood dysregulation disorderPsychiatric disorders | 0/209 | 0/211 | 1/208 | 0/211 |
| Respiratory tract infection viralInfections and infestations | 1/209 | 0/211 | 0/208 | 0/211 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/209 | 1/211 | 0/208 | 0/211 |
| LymphadenitisBlood and lymphatic system disorders | 0/209 | 0/211 | 0/208 | 1/211 |
| PyrexiaGeneral disorders | 0/209 | 0/211 | 0/208 | 1/211 |
| Pneumonia mycoplasmalInfections and infestations | 0/209 | 1/211 | 0/208 | 0/211 |
| HeadacheNervous system disorders | 0/209 | 0/211 | 0/208 | 1/211 |
| Partial seizuresNervous system disorders | 0/209 | 0/211 | 0/208 | 1/211 |
| Event | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/209 | 8/211 | 11/208 | 9/211 |
Intent-to-treat (ITT) analysis set included all randomized participants.
| Age, Continuous(years) | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID | Total |
|---|---|---|---|---|---|
| Mean | 8.5 ± 1.98 | 8.7 ± 1.83 | 8.5 ± 1.94 | 8.4 ± 2.05 | 8.5 ± 1.95 |
| Sex: Female, Male(Participants) | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID | Total |
|---|---|---|---|---|---|
| Female | 79 | 74 | 80 | 91 | 324 |
| Male | 130 | 137 | 130 | 120 | 517 |
| Race/Ethnicity, Customized(Participants) | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID | Total |
|---|---|---|---|---|---|
| White | 172 | 168 | 171 | 172 | 683 |
| Black or African American | 33 | 41 | 32 | 29 | 135 |
| Asian | 1 | 0 | 2 | 3 | 6 |
| American Indian or Alaska Native | 0 | 1 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Other | 2 | 1 | 3 | 7 | 13 |
| At-Home Baseline Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)(percent predicted of FEV1) | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID | Total |
|---|---|---|---|---|---|
| Mean | 68.8 ± 9.70 | 69.6 ± 9.68 | 69.6 ± 9.47 | 69.9 ± 9.15 | 69.5 ± 9.49 |
| In-Clinic Baseline Percent Predicted FEV1(percent predicted of FEV1) | Placebo MDPI | Fp MDPI 25 mcg BID | Fp MDPI 50 mcg BID | FS MDPI 50/12.5 mcg BID | Total |
|---|---|---|---|---|---|
| Mean | 74.9 ± 14.58 | 73.0 ± 13.43 | 72.9 ± 13.00 | 74.1 ± 15.02 | 73.7 ± 14.03 |
Showing the first 100 of 118 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Apr 2019, 27 months.
Results were first posted in Mar 2020, 11 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate
Teva Branded Pharmaceutical Products R&D, Inc. →